DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Pennsylvania Convention Center

2016年6月26日 (日) 午後 1:00 - 2016年6月26日 (日) 午後 4:30

1101 Arch Street, , Philadelphia, PA 19107 , USA

#30: Japan Regulatory Environment: Overview of the Organization, Processes, Systems, and Changes Affecting Pharmaceutical Development

概要

An additional registration fee is required for all preconference tutorials. Register today for this tutorial.

Significant changes in Japanese pharmaceutical regulations and procedures are impacting the development of new drugs in Japan as well as global development programs. This tutorial will describe the major drivers of the regulatory system, including the Pharmaceuticals and Medical Devices Agency (PMDA) and Ministry of Health, Labor and Welfare (MHLW), regulatory procedures during drug development (Consultations with PMDA and Clinical Trial Notifications), the integration of Japanese drug development with East Asian and global drug development, accelerated approval pathways (sakigake; regenerative medicine), orphan drug regulation and J-NDA review. Several development strategies available to address Japanese requirements for new drug approval, as well as selected post-approval requirements, will be discussed.

参加対象

This tutorial is designed for professionals involved in regulatory affairs, project management, and clinical development who are involved with global development projects involving Japan.

学習目的

  • Explain the major elements of the Japanese regulatory system;
  • Describe the regulatory procedures during development, registration, and post-approval;
  • Discuss specific attributes of the Japanese regulatory system and their impact on local and global development strategies.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。